Literature DB >> 20862482

[Biologics and cardiovascular risk].

I H Tarner1, U Müller-Ladner, C Hamm.   

Abstract

Over the course of the last decade, biologic response modifiers (biologics) have significantly broadened the therapeutic armamentarium in clinical rheumatology. In addition to their impressive efficacy, they have also received considerable attention regarding their adverse effects. In contrast to the risk of severe infections and malignancies, the cardiovascular risk of these drugs has provoked less vigilance. This article reviews the current data on the cardiovascular effects and adverse effects of biologics.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20862482     DOI： 10.1007/s00393-009-0583-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  41 in total

Review 1.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

2.  Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab.

Authors:  C Gonzalez-Juanatey; J Llorca; A Sanchez-Andrade; C Garcia-Porrua; J Martin; M A Gonzalez-Gay
Journal:  Clin Exp Rheumatol       Date:  2006 May-Jun       Impact factor: 4.473

3.  Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis.

Authors:  Pierpaolo Di Micco; Paola Ferrazzi; Luca Librè; Loredana Mendolicchio; Ilaria Quaglia; Monica De Marco; Anna Colombo; Monica Bacci; Lidia Luciana Rota; Corrado Lodigiani
Journal:  Int J Gen Med       Date:  2009-07-30

4.  Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.

Authors:  P I Sidiropoulos; P Siakka; K Pagonidis; A Raptopoulou; H Kritikos; D Tsetis; D T Boumpas
Journal:  Scand J Rheumatol       Date:  2009 Jan-Feb       Impact factor: 3.641

5.  Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart.

Authors:  G Torre-Amione; S Kapadia; J Lee; J B Durand; R D Bies; J B Young; D L Mann
Journal:  Circulation       Date:  1996-02-15       Impact factor: 29.690

6.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

Authors:  Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

7.  Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis.

Authors:  I C van Eijk; M K de Vries; J H M Levels; M J L Peters; E E Huizer; B A C Dijkmans; I E van der Horst-Bruinsma; B P C Hazenberg; R J van de Stadt; G J Wolbink; M T Nurmohamed
Journal:  Arthritis Rheum       Date:  2009-05

8.  Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Authors:  Joachim Listing; Anja Strangfeld; Jörn Kekow; Matthias Schneider; Andreas Kapelle; Siegfried Wassenberg; Angela Zink
Journal:  Arthritis Rheum       Date:  2008-03

9.  Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

Authors:  Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming
Journal:  Circulation       Date:  2004-03-15       Impact factor: 29.690

10.  Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

Authors:  N Nishimoto; N Miyasaka; K Yamamoto; S Kawai; T Takeuchi; J Azuma
Journal:  Ann Rheum Dis       Date:  2008-11-19       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.